Newsletter | February 24, 2026
FEATURED EDITORIAL
Rethinking Disease Modification Through Targeted Immunotherapy
By David Moss, CEO and cofounder, INmune Bio, Inc.
As understanding of immune-driven disease deepens, therapies that selectively correct dysregulated inflammation have the potential to reshape treatment paradigms.
MOST POPULAR NEWS
•
QuidelOrtho Enters Strategic Supply Agreement To Expand Global Immunoassay Portfolio
Bio-Techne's Ella Platform Achieves CE-IVD Marking
FDA 510(k) Clearance Establishes Broad Intended Use For Copan's PhenoMATRIX
Waters Introduces Next-Gen Microflow LC Columns With MaxPeak Premier Technology
LEX Diagnostics Receives FDA 510(k) Clearance And CLIA Waiver For LEX VELO System
Meridian Life Science Launches Its Lyophilized NGS Enzymatic DNA Fragmentation Kit
Parse Biosciences Launches Evercode Whole Transcriptome V4 Product Line
Project Santa Fe Foundation & Virchow Medical Announce First-Of-Its-Kind Partnership
DEXIS Advances Digital Dentistry With Enhanced Lab-To-Clinic Workflow Solutions
Breath Diagnostics, Inc. Receives FDA Breakthrough Device Designation For OneBreath Platform
Molecular Instruments Announces Fully Ambient-Temperature HCR Pro RNA-ISH On The BOND-III
